Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
UNCY Stock Forecast 2026-2027
$6.92
Current Price
$184.76M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to UNCY Price Targets
+1,200.6%
To High Target of $90.00
+384.1%
To Median Target of $33.50
+160.1%
To Low Target of $18.00
UNCY Price Momentum
-4.3%
1 Week Change
-12.8%
1 Month Change
-23.1%
1 Year Change
+19.9%
Year-to-Date Change
-37.1%
From 52W High of $11.00
+86.5%
From 52W Low of $3.71
📊 TOP ANALYST CALLS
Did UNCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Unicycive is one of their latest high-conviction picks.
Latest UNCY Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, UNCY has a bullish consensus with a median price target of $33.50 (ranging from $18.00 to $90.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.92, the median forecast implies a 384.1% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Bruce Jackson at Benchmark, suggesting a 160.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UNCY Analyst Ratings
10
Buy
0
Hold
0
Sell
UNCY Price Target Range
Low
$18.00
Average
$33.50
High
$90.00
Current: $6.92
Latest UNCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UNCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $18.00 |
| May 13, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 6, 2026 | Benchmark | Speculative Buy | Maintains | $N/A | |
| Apr 2, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Oct 29, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 15, 2025 | Benchmark | Speculative Buy | Maintains | $N/A | |
| May 27, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $9.00 |
| Apr 21, 2025 | Guggenheim | Buy | Initiates | $N/A | |
| Apr 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 29, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 22, 2024 | Benchmark | Speculative Buy | Reiterates | $N/A | |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 9, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 6, 2024 | Benchmark | Speculative Buy | Reiterates | $N/A | |
| Sep 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Unicycive Therapeutics Inc. (UNCY) Competitors
The following stocks are similar to Unicycive based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Unicycive Therapeutics Inc. (UNCY) Financial Data
Unicycive Therapeutics Inc. has a market capitalization of $184.76M with a P/E ratio of -4.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -163.1%.
Valuation Metrics
Market Cap
$184.76M
Enterprise Value
$130.99M
P/E Ratio
-4.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.5%
Current Ratio
2.4x
Debt/Equity
2.2x
ROE
-163.1%
ROA
-40.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Unicycive Therapeutics Inc. (UNCY) Business Model
About Unicycive Therapeutics Inc.
What They Do
Develops therapies for kidney disease.
Business Model
The company focuses on creating and commercializing innovative treatments for kidney disease, particularly targeting unmet needs in nephrology. It generates revenue through the development of novel therapies and potential partnerships with industry and academic entities for research and commercialization.
Additional Information
Unicycive Therapeutics is dedicated to improving patient outcomes in chronic kidney disease, with a specific focus on addressing complications like hyperphosphatemia. The company employs advanced drug discovery techniques and operates in a highly competitive market, aiming to drive significant advancements in kidney therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Dr. Shalabh K. Gupta M.D., MPA
Country
United States
IPO Year
2021
Website
unicycive.comUnicycive Therapeutics Inc. (UNCY) Latest News & Analysis
Latest News
Quick Summary
Unicycive Therapeutics is valued at $8/share, with $2 in cash and a pipeline primarily focused on OLC, targeting hyperphosphatemia. PDUFA date is June 29, 2026; risks include pricing and patent issues.
Why It Matters
Unicycive's valuation reflects its pipeline potential and cash reserves. The success of OLC in reducing pill burden is crucial for market acceptance, impacting future revenue and share price.
Source: Seeking Alpha
Market Sentiment:
Neutral
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
27 days ago
Quick Summary
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) reported its Q1 2026 financial results and provided a business update focused on its kidney disease therapies.
Why It Matters
Unicycive's Q1 financial results and business update can signal performance trends and future prospects, impacting stock valuation and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
1 month ago
Quick Summary
Unicycive Therapeutics, Inc. (UNCY) presented at the 25th Annual Needham Virtual Healthcare Conference, highlighting developments in its healthcare initiatives.
Why It Matters
Unicycive's presentation at a major healthcare conference could signal new insights into its pipeline or strategy, influencing investor perception and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kuehn Law is investigating Unicycive Therapeutics (NASDAQ: UNCY) for potential breaches of fiduciary duties by its officers and directors related to misrepresentations about FDA compliance and regulatory prospects.
Why It Matters
Shareholder litigation suggests potential legal and financial risks for Unicycive Therapeutics, which could negatively impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
1 month ago
Quick Summary
Unicycive Therapeutics (Nasdaq: UNCY) will have CEO Shalabh Gupta present at the Needham Virtual Healthcare Conference on April 15, 2026, at 3:45 p.m. ET.
Why It Matters
Unicycive's CEO presentation may signal potential developments in its kidney disease therapies, influencing investor confidence and stock performance based on insights shared at the conference.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
2 months ago
Quick Summary
Unicycive Therapeutics (Nasdaq: UNCY) reported its 2025 financial results and provided a business update on March 30, 2026, focusing on therapies for kidney disease.
Why It Matters
Unicycive's financial results and business update may influence stock performance, reflecting its progress in developing kidney disease therapies and potential market impact.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About UNCY Stock
What is Unicycive Therapeutics Inc.'s (UNCY) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Unicycive Therapeutics Inc. (UNCY) has a median price target of $33.50. The highest price target is $90.00 and the lowest is $18.00.
Is UNCY stock a good investment in 2026?
According to current analyst ratings, UNCY has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UNCY stock?
Wall Street analysts predict UNCY stock could reach $33.50 in the next 12 months. This represents a 384.1% increase from the current price of $6.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Unicycive Therapeutics Inc.'s business model?
The company focuses on creating and commercializing innovative treatments for kidney disease, particularly targeting unmet needs in nephrology. It generates revenue through the development of novel therapies and potential partnerships with industry and academic entities for research and commercialization.
What is the highest forecasted price for UNCY Unicycive Therapeutics Inc.?
The highest price target for UNCY is $90.00 from at , which represents a 1,200.6% increase from the current price of $6.92.
What is the lowest forecasted price for UNCY Unicycive Therapeutics Inc.?
The lowest price target for UNCY is $18.00 from Bruce Jackson at Benchmark, which represents a 160.1% increase from the current price of $6.92.
What is the overall UNCY consensus from analysts for Unicycive Therapeutics Inc.?
The overall analyst consensus for UNCY is bullish. Out of 3 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.50.
How accurate are UNCY stock price projections?
Stock price projections, including those for Unicycive Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 5:39 PM UTC